SCHEMBL4927870

SCHEMBL4927870

Cc1c(Br)cc(COCC(F)(F)F)cc1Br

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TACR1 P25103 3/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPK1 P28482 1/20 0.33
IDO1 P14902 2/20 0.32
RPS6KB1 P23443 1/20 0.32
AKT1 P31749 1/20 0.32
AMD1 P17707 1/20 0.32
LMNA P02545 1/20 0.32
AR P10275 1/20 0.31
CACNA1F O60840 1/20 0.30
CACNA1D Q01668 1/20 0.30
CACNA1S Q13698 1/20 0.30
CACNA1C Q13936 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23454357 0.77 ALDH1A1 (0.45) ALDH1A1TACR1MEN1KMT2AMAPT
SCHEMBL2462180 0.76 ALDH1A1 (0.36) ALDH1A1TACR1KMT2AIDO1
SCHEMBL18491297 0.71 ALDH1A1 (0.46) ALDH1A1TACR1MEN1KMT2AMAPT
SCHEMBL27099348 0.71 SMN1; SMN2 (0.35) ALDH1A1MAPTCYP3A4IDO1
SCHEMBL13698753 0.71 ALDH1A1 (0.58) ALDH1A1TACR1MEN1KMT2AMAPT
SCHEMBL23454355 0.71 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AMAPTCYP3A4
SCHEMBL31617705 0.70 ALDH1A1 (0.49) ALDH1A1TACR1MEN1KMT2AMAPT
SCHEMBL14750058 0.69 IDO1 (0.55) ALDH1A1IDO1LMNAAR
SCHEMBL10202607 0.69 IDO1 (0.55) ALDH1A1TACR1IDO1LMNAAR
SCHEMBL31128371 0.68 MBOAT4 (0.32) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 ALDH1A1 4305/4885TACR1 2290/4885MEN1 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.